Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer
about
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapyTrials with 'epigenetic' drugs: an updateHistone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?Histone deacetylase inhibitors: emerging mechanisms of resistance.Small cell lung cancer: will recent progress lead to improved outcomes?Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapyRomidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.Scheduling of anticancer drugs: timing may be everything.Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies.Epigenetic therapy in lung cancer.Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancerThe development of targeted therapy in small cell lung cancer.Phase I trial of a new schedule of romidepsin in patients with advanced cancers.Epigenetic therapy for solid tumors: from bench science to clinical trials.Histone Deacetylase Inhibitors as Anticancer Drugs.The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation.An unusual neck tumor in a young pregnant woman: challenge diagnosis and response to treatmentThe Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.
P2860
Q24609974-ED0BA24E-EB2E-4F11-A3D4-4CEA828ED3D4Q27000542-389C922C-AE9D-4784-BF9B-383D047321ACQ30251920-FC0A88B5-6821-4F17-80A7-58C56FF52095Q33417499-D83008A6-D9A4-4D04-ADF9-7FD0F923A08EQ34307356-2DECF0EF-5852-4B7C-ACF4-38B2D2441CFDQ34371189-9FFE1579-0A8B-486F-B5C0-DD354BADD682Q35592607-E223FEA7-2F1E-46DA-AE94-7C2755717DFCQ35836257-FE9B4F3E-BC14-4165-8D7A-8A544F482D16Q36088241-56A36B92-DFFA-4852-8D25-60910693E073Q36521908-4B95247F-BD36-4B94-9935-74BB45CB1F12Q36556304-683538D8-A480-4AD6-B57B-03EF4494016EQ36787517-269EBC2E-4E85-4BAE-9337-8289FE3E322EQ36885903-60612140-5180-4D9C-B52F-888059CC1DB6Q36926148-0C26136F-9343-49F5-BED8-C664AB12F563Q37093273-2822A4AA-7EE6-491F-ADC1-C69078D50A23Q37127932-241F4B06-25AB-4C7E-A310-6F9AAEA5ED12Q37667088-22872333-4AC5-4453-80FE-4B7204A0139AQ38459836-17F733EF-EBC1-409E-8F3F-4D292893396DQ38696932-09981DB8-1071-4EAD-AD69-C5DBF0DDD258Q38878715-97F1E48B-135D-4A74-92B6-C372DBB295FAQ39248784-1E107668-E8A5-4104-80D8-0AA3BE3743C6Q39372689-635C6A78-C371-432D-829F-9385D700AF10Q39392171-3AC68A19-DF08-4EA4-8140-F8E265300860Q41510042-318D9AF9-EFF2-4523-83AB-B115348D8E25Q48303460-7E8006DC-BECA-487A-905B-4938DB8FF6AB
P2860
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Schedule-dependent synergy of ...... ents in small cell lung cancer
@ast
Schedule-dependent synergy of ...... ents in small cell lung cancer
@en
type
label
Schedule-dependent synergy of ...... ents in small cell lung cancer
@ast
Schedule-dependent synergy of ...... ents in small cell lung cancer
@en
prefLabel
Schedule-dependent synergy of ...... ents in small cell lung cancer
@ast
Schedule-dependent synergy of ...... ents in small cell lung cancer
@en
P2093
P2860
P356
P1433
P1476
Schedule-dependent synergy of ...... ents in small cell lung cancer
@en
P2093
Crystal D Salcido
Edina Komlodi-Pasztor
Keli Agama
Lyuba Varticovski
Robert F Murphy
Susan E Bates
Victoria L Luchenko
Yves Pommier
P2860
P304
P356
10.4161/CC.10.18.17190
P577
2011-09-15T00:00:00Z